Four board members forced out at QRxPharma

Bowing to pressure from disgruntled institutional shareholders, four members of QRxPharma's (QRXPY -2.4%) BOD resign, including Chairman Dr. Peter Farrell, prior to today's General Meeting of shareholders. The source of the discontent is management's failure to earn FDA approval for its lead product Moxduo, a combo analgesic of morphine and oxycodone. The NDA was filed in November 2013 but received a negative Ad Comm vote on April 22, 2014 and a subsequent thumbs down from the agency.

Comments (1)
  • sheepery
    , contributor
    Comments (3) | Send Message
    Well it will be interesting to see where we go from here.
    9 Jul 2014, 11:23 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs